Customize your search results with filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 01/21/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 632 publications
Immunogenic shift of arginine metabolism triggers systemic metabolic and immunological reprogramming to prevent HER2+ breast cancer.
Journal: bioRxiv : the preprint server for biology
Published: November 01, 2024
DLL4-targeted CAR-T therapy sensitizes neoadjuvant chemotherapy via eliminating cancer stem cells and reshaping immune microenvironment in HER2+ breast cancer.
Journal: Journal for immunotherapy of cancer
Published: October 18, 2024
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Setting.
Journal: Current oncology (Toronto, Ont.)
Published: September 20, 2024
Assessing Neurohormonal Antagonist Withdrawal in HER2+ Breast Cancer Patients With CTRCD.
Journal: JACC. CardioOncology
Published: September 06, 2024
Letter to the editor: Comment on "possible protective effect of rosuvastatin in chemotherapy-induced cardiotoxicity in HER2 positive breast cancer patients: a randomized controlled trial".
Journal: Medical oncology (Northwood, London, England)
Published: September 05, 2024
Impaired cyclin D3 protein degradation contributes to trastuzumab resistance in HER2 positive breast cancer.
Journal: Medical oncology (Northwood, London, England)
Published: August 26, 2024
Sonodynamic Therapy for HER2+ Breast Cancer with Iodinated Heptamethine Cyanine-Trastuzumab Conjugate.
Journal: International journal of molecular sciences
Published: August 22, 2024
ASO Visual Abstract: Change in Biomarker Profile After Neoadjuvant Chemotherapy is Prognostic and is Common in Patients with HER2+ Breast Cancer.
Journal: Annals of surgical oncology
Published: August 19, 2024
Multi-institutional report of trastuzumab deruxtecan and stereotactic radiosurgery for HER2 positive and HER2-low breast cancer brain metastases.
Journal: NPJ breast cancer
Published: July 29, 2024
Differences in axillary response and treatment implications in HER2 positive node positive breast cancer during neoadjuvant HER2 targeted dual therapy.
Journal: Scientific reports
Published: July 22, 2024
Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial).
Journal: JCO oncology practice
Published: July 19, 2024
Last Updated: 01/21/2025